1) Bymaster FP, Lee TC, Knadler MP, et al:The dual transporter inhibitor duloxetine:A review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 11:1475-1493, 2005
2) Detke MJ, Lu Y, Goldstein DJ, et al:Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 36:383-390, 2002
3) 福田一彦,小林重雄:自己評価式抑性尺度の研究.精神神経学雑誌75:673-679, 1973
4) Guy W:Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology, reviseded. NIMH, Rockville, pp217-222, 1976
5) 樋口輝彦,村崎光邦,上島国利:Duloxetineの大うつ病性障害に対する臨床評価―Placebo及びparoxetineを対照薬とした二重盲検比較試験.臨床精神薬理12:1613-1634, 2009
6) Kihara T, Ikeda M:Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frotal cortex. J Pharmacol Exp Ther 272:177-183, 1995
7) 厚生労働省:平成23年(2011)患者調査の概況.2012年11月27日.(http://www.mhlw.go.jp/toukei/saikin/hw/kanja/11/index.html)
8) Nelson JC, Lu Pritchett Y, Martynov O, et al:The safety and tolerability of duloxetine compared with paroxetine and placebo:A pooled analysis of 4 clinical trials. J Clin Psychiatry 8:212-219, 2006
9) Romera I, Pérez V, Menchón JM, et al:Early switch strategy in patients with major depressive disorder:a double-blind, randomized study. J Clin Psychopharmacol 32:479-486, 2012
10) Rosso G, Rigardetto S, Bogetto F, et al:A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. J Affect Disord 136:172-176, 2012
11) Sawada N, Uchida H, Suzuki T, et al:Persistence and compliance to antidepressant treatment in patients with depression:A chart review. BMC Psychiatry 9:38, 2009